Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy.

@article{JabbarzadehKaboli2020AkttargetedTA,
  title={Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy.},
  author={Parham Jabbarzadeh Kaboli and Fatemeh Salimian and Sevil Aghapour and Shixin Xiang and Qijie Zhao and Mingxing Li and Xu Wu and Fukuan Du and Yueshui Zhao and Jing Shen and Chi Hin Cho and Zhangang Xiao},
  journal={Pharmacological research},
  year={2020},
  pages={
          104806
        }
}
Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy.
TLDR
It is shown that sustained activation of Akt results in resistance to different types of chemotherapy, and Akt signalling plays a cellular defence role against chemotherapy and enhances multi-drug resistance, and increases reactive oxygen species at breast tumor microenvironment.
New Advances in Targeted Therapy of HER2-Negative Breast Cancer
TLDR
The potential targets that may be used for breast cancer treatment from the aspects of PI3K/AKT signaling pathway, DDR, angiogenesis, the cell cycle, breast cancer stem cells, etc., are described and possible inhibitors for the treatment of HER2-negative breast cancer are explored.
The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer
TLDR
Insight is provided into better understanding the mutational landscape of BCSCs and exploring potential molecular signaling pathways targetingBCSCs to overcome chemoresistance and prevent metastasis in TNBC, ultimately to improve the overall survival of patients with this devastating disease.
Drug-Induced Resistance and Phenotypic Switch in Triple-Negative Breast Cancer Can Be Controlled via Resolution and Targeting of Individualized Signaling Signatures
TLDR
It is experimentally demonstrated that monotherapies or drug combinations that are not adjusted accurately to the patient-specific ongoing processes may create an evolutionary pressure on a tumor leading to the emergence of previously undetected or untargeted cellular subpopulations.
FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway
TLDR
It is demonstrated that FGFC1 selectively suppressed the growth of NSCLC cells with EGFR mutation and may be a potential candidate for erlotinib-resistantNSCLC therapy.
Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways
TLDR
The signaling pathways involved in the development of tumor drug resistance, including Epidermal growth factor receptor, Renin-angiotensin system (Ras), Phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), Wnt, Notch, Transforming growth factor-beta (TGF-β), and their specific signaling pathway inhibitors derived from natural products are reviewed.
Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study
TLDR
CtDNA detection at baseline was associated with shorter PFS in patients included in the TAKTIC trial, and plasma‐based copy number analysis may help to identify alterations involved in resistance to treatment.
Targeting Disseminated Estrogen-Receptor-Positive Breast Cancer Cells in Bone Marrow
TLDR
3D co-culture model data establish an integrated experimental system to investigate DTCs in bone marrow and identify combination therapy against metabolic and kinase targets as a promising approach to effectively target these cells and reduce risk of recurrence in breast cancer.
Nicotine treatment regulates PD-L1 and PD-L2 expression via inhibition of Akt pathway in HER2-type breast cancer cells
TLDR
Results show that nicotine regulates the expression of immune checkpoint molecules, PD-L1 andPD-L2, via inhibition of Akt phosphorylation, which may provide the new therapeutic strategies for the treatment of breast cancer.
Targeting AKT with costunolide suppresses the growth of colorectal cancer cells and induces apoptosis in vitro and in vivo
TLDR
The mechanism underlying the biological activity of CTD in colon cancer is uncovered and it is revealed that CTD might be a new AKT inhibitor in Colon cancer treatment, and CTD is worthy of further exploration in preclinical and clinical trials.
...
...

References

SHOWING 1-10 OF 199 REFERENCES
PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer
TLDR
The findings provide novel insights into the molecular mechanisms/signaling pathways by which atezolizumab exerts inhibitory effects on TNBC, thereby inhibiting EMT/metastasis, tumor growth/survival, and the induction of hypoxia.
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
TLDR
It is reported that interleukin-1 receptor-associated kinase 1 (IRAK1) is overexpressed in a subset of breast cancers, in particular triple-negative breast cancer (TNBC), where it acts to drive aggressive growth, metastasis and acquired resistance to paclitaxel treatment.
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
TLDR
The pipeline of Akt inhibitors and their preclinical and clinical examination status are explored, presenting the potential clinical application of these agents as a monotherapy or in combination with ionizing radiation, other targeted therapies, or chemotherapy.
Recent Development in Indole Derivatives as Anticancer Agents for Breast Cancer.
  • K. Kaur, V. Jaitak
  • Chemistry, Biology
    Anti-cancer agents in medicinal chemistry
  • 2019
TLDR
Indole derivatives seem to be quite competent and acting through various mechanisms that are well established in case of BC, and a lot of potential is still hidden which demands to be discovered for upgrading of BC chemotherapy.
Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells
TLDR
Results demonstrate that HIF expression and transcriptional activity are induced by treatment of MDA-MB-231, SUM-149, and SUM-159, which are human TNBC cell lines, as well as MCF-7, which is an ER+/PR+ breast cancer line, with paclitaxel or gemcitabine.
CIP2A is a target of bortezomib in human triple negative breast cancer cells
TLDR
CIP2A is a major determinant mediating bortezomib-induced apoptosis in TNBC cells and may be a potential therapeutic target in T NBC, which currently has no specific therapeutic targets.
Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer
TLDR
It is shown that resistance to MK2206 is reversible because upon drug removal resistant cells regain sensitivity to AKT inhibition, accompanied by reexpression of epithelial markers and reduction of AKT3 expression, implying that epigenetic reprogramming contributes to acquisition of resistance.
Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth
TLDR
Results indicate AKT-HSF1 signaling mediates breast cancer stem cells self-renewal, tumor growth and metastasis, and that dual targeting of AKT and HSF1 resulted in synergistic suppression of breast cancer progression thereby supporting future testing of AKt-HSf1 combination therapy for breast cancer patients.
...
...